OSTX
OS Therapies Incorporated (OSTX) Reports FY2025 Earnings
OS Therapies Incorporated posted a loss per share of $0.
OS Therapies CEO On Osteosarcoma Treatment
Paul Romness, CEO of OS Therapies, discusses the company's commitment to developing treatments for osteosarcoma. On Unmet Need Q: Why…